Alimera Sciences to Report First Quarter 2016 Financial Results on May 4, 2016
Get Alerts ALIM Hot Sheet
Join SI Premium – FREE
ATLANTA, April 26, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ: ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the period ended March 31st, 2016, at the close of the financial markets on May 4, 2016.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 10:00 AM ET, on May 5, 2016. Please refer to the information below for conference call dial-in information and webcast registration.
Conference date: May 5, 2016, 10:00 AM ETConference dial-in: 877-269-7756International dial-in: 201-689-7817Conference Call Name: Alimera Sciences First Quarter 2015 Results Call Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera SciencesAlimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Our commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact: COCKRELL GROUP 877.889.1972 [email protected] cockrellgroup.comSource: Alimera Sciences, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- Synovus Financial (SNV) Misses Q1 EPS by 20c
- Micron stock recovers on report of over $6 bln in CHIPS Act grants
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!